Reorganization and consolidation of the US and European business functions centered on Deciphera
First written in FY2025. 2 of 5 entries say "Advanced", first in 2026-05-08. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AchievedAnnual report
「In addition, we positioned the company as the base for our US and European operations and reorganized and consolidated the functions previously maintained in the US and the UK. This will enable us to further accelerate our global operations as an integrated Group.」
It was stated that the reorganization and consolidation of the US and UK functions, with Deciphera as the base for the US and European operations, had been completed, moving from the planning stage in the previous fiscal year to implementation. - FY2026-H1RestatedAnnual report
「To maximize the value of new drug candidates, we will formulate development and clinical trial plans capable of achieving approvals in Japan, the US and Europe as quickly as possible, while making maximum use of Deciphera’s development functions in the US and Europe, which joined the Group last year, and working to steadily conduct and execute international joint trials.」
The policy of using Deciphera’s development functions in the US and Europe to pursue approvals and international joint trials in Japan, the US and Europe has been reconfirmed. - FY2025First statedAnnual report
「In addition, using Deciphera as the base for our US and European operations, we will reorganize and consolidate the functions previously maintained in the US and the UK. This will enable us to further accelerate our global operations as an integrated Group.」
The reorganization and consolidation of the US and UK functions following the acquisition of Deciphera was explicitly identified for the first time as an independent initiative to accelerate the global business.